Brandon Turner1, Nitya Rajeshuni1, Elaine M Tran1, Cassie A Ludwig2, Zujaja Tauqeer3, Brannon Weeks1, Benyam Kinde4, Suzann Pershing5. 1. Stanford University School of Medicine, Stanford, California, USA. 2. Department of Ophthalmology, Byers Eye Institute, Stanford University, Palo Alto, California, USA. 3. Department of Ophthalmology, Scheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania, USA. 4. Department of Ophthalmology, University of California San Francisco, San Francisco, California, USA. 5. Department of Ophthalmology, Byers Eye Institute, Stanford University, Palo Alto, California, USA; Veterans Affairs Palo Alto Health California System, Palo Alto, California, USA. Electronic address: pershing@stanford.edu.
Abstract
PURPOSE: To perform a comprehensive analysis of characteristics of ophthalmology trials registered in ClinicalTrials.gov. DESIGN: Cross-sectional study. METHODS: All 4,203 ophthalmologic clinical trials registered on ClinicalTrials.gov between October 1, 2007, and April 30, 2018, were identified by using medical subject headings (MeSH). Disease condition terms were verified by manual review. Trial characteristics were assessed through frequency calculations. Hazard ratios and 95% confidence intervals were determined for characteristics associated with early discontinuation. RESULTS: The majority of trials were multiarmed (73.6%), single-site (69.4%), randomized (64.8%), and had <100 enrollees (66.3%). A total of 33% used a data-monitoring committee (DMC), and 50.6% incorporated blinding. Other groups (51.6%) were funded by industry, whereas 2.6% were funded by the US National Institutes of Health (NIH). NIH trials were significantly more likely to address oncologic (NIH = 15.5%, Other = 3%, Industry = 1.5%; P < 0.001) or pediatric disease (NIH = 20.9%, Other = 5.9%, Industry = 1.4%; P < 0.001). Industry-sponsored trials (69.6% of phase 3 trials) were significantly more likely to be randomized (Industry = 68.7%, NIH = 58.9%, Other = 60.8%; P < 0.001) and blinded (Industry = 57.2%, NIH = 42.7%, Other = 43.5%; P < 0.001). A total of 359 trials (8.5%) were discontinued early, and 530 trials (12.6%) had unknown status. Trials were less likely to be discontinued if funded by sources other than industry (hazard ratio [HR], 0.72; 95% confidence interval [CI], 0.55-0.95; P = 0.021) and/or had a DMC (HR, 0.71; 95% CI, 0.55-0.92; P = 0.010). CONCLUSIONS: Ophthalmology trials in the past decade reveal heterogeneity across study funding sources. NIH trials were more likely to support historically underfunded subspecialties, whereas Industry trials were more likely to face early discontinuation. These trends emphasize the importance of carefully monitored and methodologically sound trials with deliberate funding allocation. Published by Elsevier Inc.
PURPOSE: To perform a comprehensive analysis of characteristics of ophthalmology trials registered in ClinicalTrials.gov. DESIGN: Cross-sectional study. METHODS: All 4,203 ophthalmologic clinical trials registered on ClinicalTrials.gov between October 1, 2007, and April 30, 2018, were identified by using medical subject headings (MeSH). Disease condition terms were verified by manual review. Trial characteristics were assessed through frequency calculations. Hazard ratios and 95% confidence intervals were determined for characteristics associated with early discontinuation. RESULTS: The majority of trials were multiarmed (73.6%), single-site (69.4%), randomized (64.8%), and had <100 enrollees (66.3%). A total of 33% used a data-monitoring committee (DMC), and 50.6% incorporated blinding. Other groups (51.6%) were funded by industry, whereas 2.6% were funded by the US National Institutes of Health (NIH). NIH trials were significantly more likely to address oncologic (NIH = 15.5%, Other = 3%, Industry = 1.5%; P < 0.001) or pediatric disease (NIH = 20.9%, Other = 5.9%, Industry = 1.4%; P < 0.001). Industry-sponsored trials (69.6% of phase 3 trials) were significantly more likely to be randomized (Industry = 68.7%, NIH = 58.9%, Other = 60.8%; P < 0.001) and blinded (Industry = 57.2%, NIH = 42.7%, Other = 43.5%; P < 0.001). A total of 359 trials (8.5%) were discontinued early, and 530 trials (12.6%) had unknown status. Trials were less likely to be discontinued if funded by sources other than industry (hazard ratio [HR], 0.72; 95% confidence interval [CI], 0.55-0.95; P = 0.021) and/or had a DMC (HR, 0.71; 95% CI, 0.55-0.92; P = 0.010). CONCLUSIONS: Ophthalmology trials in the past decade reveal heterogeneity across study funding sources. NIH trials were more likely to support historically underfunded subspecialties, whereas Industry trials were more likely to face early discontinuation. These trends emphasize the importance of carefully monitored and methodologically sound trials with deliberate funding allocation. Published by Elsevier Inc.
Authors: Nirosha D Perera; Marija Kamceva; Jolie Z Shen; Brandon E Turner; Maya Abdou; Jecca R Steinberg; Amit Mahipal Journal: JAMA Netw Open Date: 2022-07-01
Authors: Bonnie O Wong; Nirosha D Perera; Jolie Z Shen; Brandon E Turner; Henry K Litt; Amit Mahipal; Sherry M Wren Journal: JAMA Netw Open Date: 2022-01-04
Authors: Christopher J Magnani; Jecca R Steinberg; Cécile I Harmange; Xinyuan Zhang; Conor Driscoll; Alexander Bell; Jeffrey Larson; Jonathan G You; Brannon T Weeks; Tina Hernandez-Boussard; Brandon E Turner; James D Brooks Journal: J Urol Date: 2020-10-20 Impact factor: 7.450
Authors: Darren S Thomas; Aaron Y Lee; Philipp L Müller; Roy Schwartz; Abraham Olvera-Barrios; Alasdair N Warwick; Praven J Patel; Tjebo F C Heeren; Catherine Egan; Paul Taylor; Adnan Tufail Journal: Clin Transl Sci Date: 2021-03-02 Impact factor: 4.689
Authors: Jecca R Steinberg; Brandon E Turner; Brannon T Weeks; Christopher J Magnani; Bonnie O Wong; Fatima Rodriguez; Lynn M Yee; Mark R Cullen Journal: JAMA Netw Open Date: 2021-06-01